EnAIRgy

EnAIRgy is a French biotechnology company focused on developing innovative treatments for chronic respiratory diseases, particularly Chronic Obstructive Pulmonary Disease (COPD). The company was founded as a spin-off from the Institut Pasteur de Lille and the University of Lille, based on the discovery of the role of R-Spondin 2 (RSPO2) in lung pathology. EnAIRgy's therapeutic strategy involves inhibiting the RSPO2 pathway to reduce airway inflammation and reverse tissue remodeling, offering a potential disease-modifying approach. Their lead research programs are currently in the pre-clinical stage, targeting the underlying biological drivers of obstructive lung diseases. By addressing the limitations of current bronchodilator and steroid therapies, EnAIRgy aims to provide new hope for patients with severe respiratory conditions.